EUCTR2006-005473-21-BE
Active, not recruiting
Phase 1
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 6 months -5 years old with hypertension.
ConditionsHypertension
DrugsDiovan 160
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Hypertension
- Sponsor
- ovartis Pharma Services AG
- Enrollment
- 66
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who qualified and entered core study CVAL489K2303
- •2\. Patients who participated in the core study CVAL489K2303, completed period 1
- •and were re\-randomized in period 2 and continued for at least 3 days in period 2\.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\. Patients who did not complete period 1 of the core study.
- •2\. Patients who were re\-reandomized in period 2 of core study but did not continue
- •for \=3 days in period 2 of the core study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-HUovartis Pharma Services AG68
Active, not recruiting
Not Applicable
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.EUCTR2006-005473-21-DEovartis Pharma Services AG68
Active, not recruiting
Phase 1
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionEUCTR2006-005473-21-FRovartis Pharma Services AG66
Active, not recruiting
Phase 1
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-GBovartis Pharma Services AG66
Active, not recruiting
Not Applicable
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-SEovartis Pharma Services AG68